FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147757009> ?p ?o ?g. }

• W2147757009 endingPage "963" @default.
• W2147757009 startingPage "955" @default.
• W2147757009 abstract "We investigated rituximab maintenance therapy in patients with diffuse large B-cell lymphoma (n=662) or follicular lymphoma grade 3b (n=21) in first complete remission. Patients were randomized to rituximab maintenance (n=338) or observation (n=345). At a median follow-up of 45 months, the event-free survival rate (the primary endpoint) at 3 years was 80.1% for rituximab maintenance versus 76.5% for observation. This difference was not statistically significant for the intent-to-treat population (likelihood ratio P=0.0670). The hazard ratio by treatment arm was 0.79 (95% confidence interval 0.57-1.08; P=0.1433). The secondary endpoint, progression-free survival was also not met for the whole statistical model (likelihood ratio P=0.3646). Of note, rituximab maintenance was superior to observation when treatment arms only were compared (hazard ratio: 0.62; 95% confidence interval 0.43-0.90; P=0.0120). Overall survival remained unchanged (92.0 versus 90.3%). In subgroup analysis male patients benefited from rituximab maintenance with regards to both event-free survival (84.1% versus 74.4%) (hazard ratio: 0.58; 95% confidence interval 0.36-0.94; P=0.0267) and progression-free survival (89.0% versus 77.6%) (hazard ratio: 0.45; 95% confidence interval 0.25-0.79; P=0.0058). Women had more grade 3/4 adverse events (P=0.0297) and infections (P=0.0341). Men with a low International Prognostic Index treated with rituximab had the best outcome. In summary, rituximab maintenance in first remission after R-CHOP-like treatment did not prolong event-free, progression-free or overall survival of patients with aggressive B-non-Hodgkin lymphoma. The significantly better outcome of men warrants further studies prior to the routine use of rituximab maintenance in men with low International Prognostic Index. This trial is registered under EUDRACT #2005-005187-90 and www.clinicaltrials.gov as #NCT00400478." @default.
• W2147757009 created "2016-06-24" @default.
• W2147757009 creator A5001243052 @default.
• W2147757009 creator A5002055787 @default.
• W2147757009 creator A5005916520 @default.
• W2147757009 creator A5015287747 @default.
• W2147757009 creator A5017763871 @default.
• W2147757009 creator A5035399907 @default.
• W2147757009 creator A5036988600 @default.
• W2147757009 creator A5039994927 @default.
• W2147757009 creator A5044848093 @default.
• W2147757009 creator A5046486904 @default.
• W2147757009 creator A5052764703 @default.
• W2147757009 creator A5055137516 @default.
• W2147757009 creator A5056600574 @default.
• W2147757009 creator A5067806282 @default.
• W2147757009 creator A5069697353 @default.
• W2147757009 creator A5073431279 @default.
• W2147757009 creator A5076735212 @default.
• W2147757009 creator A5079088048 @default.
• W2147757009 creator A5079172309 @default.
• W2147757009 creator A5083973342 @default.
• W2147757009 creator A5085541150 @default.
• W2147757009 creator A5088476247 @default.
• W2147757009 date "2015-04-24" @default.
• W2147757009 modified "2023-10-17" @default.
• W2147757009 title "Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial" @default.
• W2147757009 cites W1600734675 @default.
• W2147757009 cites W1912693401 @default.
• W2147757009 cites W1985645817 @default.
• W2147757009 cites W1997353354 @default.
• W2147757009 cites W2032685816 @default.
• W2147757009 cites W2038976306 @default.
• W2147757009 cites W2045399297 @default.
• W2147757009 cites W2055153981 @default.
• W2147757009 cites W2057221507 @default.
• W2147757009 cites W2058015212 @default.
• W2147757009 cites W2101648653 @default.
• W2147757009 cites W2102602525 @default.
• W2147757009 cites W2104095649 @default.
• W2147757009 cites W2106928992 @default.
• W2147757009 cites W2112317958 @default.
• W2147757009 cites W2113135984 @default.
• W2147757009 cites W2119147717 @default.
• W2147757009 cites W2130997237 @default.
• W2147757009 cites W2131591460 @default.
• W2147757009 cites W2139942643 @default.
• W2147757009 cites W2141226562 @default.
• W2147757009 cites W2141631842 @default.
• W2147757009 cites W2144016324 @default.
• W2147757009 cites W2144329058 @default.
• W2147757009 cites W2145304413 @default.
• W2147757009 cites W2145453495 @default.
• W2147757009 cites W2152327309 @default.
• W2147757009 cites W2153665789 @default.
• W2147757009 cites W2160305510 @default.
• W2147757009 cites W2161205944 @default.
• W2147757009 cites W2167556523 @default.
• W2147757009 cites W2598700764 @default.
• W2147757009 cites W4205736005 @default.
• W2147757009 doi "https://doi.org/10.3324/haematol.2015.125344" @default.
• W2147757009 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4486230" @default.
• W2147757009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25911553" @default.
• W2147757009 hasPublicationYear "2015" @default.
• W2147757009 type Work @default.
• W2147757009 sameAs 2147757009 @default.
• W2147757009 citedByCount "71" @default.
• W2147757009 countsByYear W21477570092015 @default.
• W2147757009 countsByYear W21477570092016 @default.
• W2147757009 countsByYear W21477570092017 @default.
• W2147757009 countsByYear W21477570092018 @default.
• W2147757009 countsByYear W21477570092019 @default.
• W2147757009 countsByYear W21477570092020 @default.
• W2147757009 countsByYear W21477570092021 @default.
• W2147757009 countsByYear W21477570092022 @default.
• W2147757009 countsByYear W21477570092023 @default.
• W2147757009 crossrefType "journal-article" @default.
• W2147757009 hasAuthorship W2147757009A5001243052 @default.
• W2147757009 hasAuthorship W2147757009A5002055787 @default.
• W2147757009 hasAuthorship W2147757009A5005916520 @default.
• W2147757009 hasAuthorship W2147757009A5015287747 @default.
• W2147757009 hasAuthorship W2147757009A5017763871 @default.
• W2147757009 hasAuthorship W2147757009A5035399907 @default.
• W2147757009 hasAuthorship W2147757009A5036988600 @default.
• W2147757009 hasAuthorship W2147757009A5039994927 @default.
• W2147757009 hasAuthorship W2147757009A5044848093 @default.
• W2147757009 hasAuthorship W2147757009A5046486904 @default.
• W2147757009 hasAuthorship W2147757009A5052764703 @default.
• W2147757009 hasAuthorship W2147757009A5055137516 @default.
• W2147757009 hasAuthorship W2147757009A5056600574 @default.
• W2147757009 hasAuthorship W2147757009A5067806282 @default.
• W2147757009 hasAuthorship W2147757009A5069697353 @default.
• W2147757009 hasAuthorship W2147757009A5073431279 @default.
• W2147757009 hasAuthorship W2147757009A5076735212 @default.
• W2147757009 hasAuthorship W2147757009A5079088048 @default.
• W2147757009 hasAuthorship W2147757009A5079172309 @default.
• W2147757009 hasAuthorship W2147757009A5083973342 @default.
• W2147757009 hasAuthorship W2147757009A5085541150 @default.

• next